查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1870328

化疗嗜中性白血球低下症市场：依产品类型、治疗方法、给药途径、最终使用者、通路、治疗环境、病患小组和剂量强度划分－2025-2032年全球预测

Chemotherapy Induced Neutropenia Market by Product Type, Therapy, Route Of Administration, End User, Distribution Channel, Treatment Setting, Patient Group, Dosage Strength - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，化疗引起的嗜中性白血球低下症市场规模将达到 107.8 亿美元，复合年增长率为 4.16%。

关键市场统计数据
基准年 2024 77.7亿美元
预计年份：2025年 81亿美元
预测年份 2032 107.8亿美元
复合年增长率 (%) 4.16%

全面概述影响化疗引起的嗜中性白血球低下症(CIN) 治疗全过程的关键临床挑战、治疗模式和相关人员优先事项。

本执行摘要探讨了化疗引起的嗜中性白血球低下症(CIN) 的临床、商业性和营运方面，这些方面正在影响整个医疗保健系统相关人员的优先事项。它重点阐述了治疗创新、交付模式和卫生经济学之间不断演变的相互作用，这些相互作用将影响患者、医疗保健提供者和製造商如何应对与细胞毒性治疗方法相关的嗜中性白血球低下症风险。其目标是对驱动治疗选择、临床转变和政策应对的因素进行简明扼要、全面阐述，并重点介绍相关人员可采取的战术性措施。

临床创新、治疗地点转移、供应链韧性和基于绩效的报销如何改变化疗引起的嗜中性白血球低下症(CIN) 的格局

近年来，技术进步、法规演变和医疗服务模式的转变显着改变了化疗引起的嗜中性白血球低下症（CIN）的现状。临床创新，例如长效粒细胞集落刺激因子（G-CSF）製剂和生物相似药的引入，丰富了治疗选择，并引入了关于给药频率、依从性和治疗部位适用性的新考虑。同时，精准癌症医学正在改善化疗方案和支持治疗流程，鼓励临床医生采用个人化的预防和治疗方法，以反映患者的风险状况和治疗目标。

了解2025年美国关税变化对治疗化疗引起的嗜嗜中性白血球低下症减少症药物的生产、采购和临床获取动态的影响

2025年美国关税的累积影响为化疗引起的嗜中性白血球低下症（CIN）治疗系统带来了新的复杂性，影响了生产策略、采购选择和价格谈判。生物製药原料和成品的关税调整迫使製造商重新评估全球采购决策，加速区域产能扩张，并在可能的情况下透过关税工程和重新分类寻求关税减免。这些策略对前置作业时间、库存管理政策和低温运输物流有着直接的营运影响，而这些对于维持G-CSF疗法的持续供应至关重要。

透过深度細項分析，将产品属性、治疗目的、给药途径和分销管道连结起来，从而製定可行的临床和商业策略。

基于细分市场的洞察揭示了影响临床实践和商业策略的各种细微机会和限制因素，涵盖了产品系列、治疗目标和供应链管道。依产品类型划分，竞争格局既包括成熟的治疗方法，例如非Filgrastim和Pegfilgrastim，也包括新型分子，例如依弗拉格司亭和长效聚乙二醇化製剂。所有这些产品在给药频率、给药便利性和低温运输要求方面都各具特色。在治疗方法中，预防性给药和治疗性给药之间的区别清晰地体现了不同的应用驱动因素：预防性给药优先考虑可预测的给药方案和依从性，而治疗性给药则强调嗜中性白血球的快速恢復和急性反应。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 扩大长效培Pegfilgrastim生物相似药的使用，以提高不同肿瘤患者群体预防性治疗的可近性和成本效益
  • 将人工智慧驱动的风险分层工具整合到临床实践中，以製定嗜中性白血球低下症减少症预防和治疗方案。
  • 在区域癌症治疗中引入口服髓系造血因子，以提高患者的便利性和用药依从性。
  • 越来越重视产生真实世界证据，以证明嗜中性白血球低下症症干预措施的成本效益和治疗结果
  • 扩大远端医疗嗜中性白血球低下症管理项目，以对农村患者群体进行远端监测和早期疗育
  • 新兴的基于价值的报销模式将嗜中性白血球低下症的治疗结果与支付方的合约和定价策略联繫起来。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章化疗嗜中性白血球低下症市场（依产品类型划分）

  • 依夫拉帕格司亭
  • Filgrastim
  • Pegfilgrastim
  • Pegfilgrastim

第九章化疗嗜中性白血球低下症市场（依治疗方法）

  • 预防
  • 治疗

第十章化疗引起的嗜中性白血球低下症市场（依给药途径划分）

  • 静脉注射
  • 皮下注射

第十一章化疗嗜中性白血球低下症市场（依最终用户划分）

  • 诊所
  • 居家照护
  • 医院

第十二章化疗引起的嗜中性白血球低下症市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十三章化疗嗜中性白血球低下症市场（依治疗方案划分）

  • 住院病人
  • 门诊

第十四章化疗嗜中性白血球低下症市场（依病患小组划分）

  • 成人
  • 老年人
  • 儿童

第十五章 依剂量强度分類的化疗引起的嗜中性白血球低下症症市场

  • 5 Mcg/Kg
  • 6 mg

第十六章化疗嗜中性白血球低下症市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十七章化疗嗜中性白血球低下症市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十八章化疗嗜中性白血球低下症市场（依国家划分）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十九章 竞争情势

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Amgen Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz International GmbH
    • Pfizer Inc.
    • Viatris Inc.
    • Biocon Ltd.
    • Fresenius Kabi AG
    • Intas Pharmaceuticals Ltd.
    • Cipla Ltd.
    • Lupin Ltd.
Product Code: MRR-1A1A064BFFBE

The Chemotherapy Induced Neutropenia Market is projected to grow by USD 10.78 billion at a CAGR of 4.16% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.77 billion
Estimated Year [2025] USD 8.10 billion
Forecast Year [2032] USD 10.78 billion
CAGR (%) 4.16%

An integrated introduction to the clinical imperatives, delivery models, and stakeholder priorities shaping responses to chemotherapy induced neutropenia across care continua

This executive summary introduces the clinical, commercial, and operational dimensions of chemotherapy induced neutropenia (CIN) that are shaping stakeholder priorities across healthcare systems. The focus here is on the evolving interplay between therapeutic innovation, delivery models, and healthcare economics that determine how patients, providers, and manufacturers respond to neutropenia risk associated with cytotoxic regimens. The objective is to present a concise, integrated account of the forces driving treatment choice, site-of-care transitions, and policy responses, while highlighting the tactical levers available to stakeholders.

Clinicians and health system leaders are increasingly balancing acute risk mitigation against long-term outcomes by integrating granulocyte colony-stimulating factor (G-CSF) strategies into broader oncology care pathways. At the same time, manufacturers and distributors contend with changing supply chain expectations and evolving reimbursement frameworks. As a result, decision-makers must synthesize clinical evidence, operational feasibility, and payer dynamics to optimize patient safety and resource utilization. This introduction sets the stage for a deeper examination of transformative shifts, regulatory and trade headwinds, segmentation-driven nuances, regional contrasts, competitive behaviors, and concrete recommendations for industry leaders.

How clinical innovation, site-of-care migration, supply chain resilience, and outcomes-driven reimbursement are collectively transforming the chemotherapy induced neutropenia landscape

Significant transformative shifts have reshaped the CIN landscape over recent years, driven by technological advances, regulatory evolution, and changing care delivery paradigms. Clinical innovation in long-acting G-CSF formulations and biosimilar entrants has diversified therapeutic options and introduced new considerations around dosing frequency, adherence, and site-of-care appropriateness. Concurrently, precision oncology has refined chemotherapy regimens and supportive care algorithms, prompting clinicians to adopt individualized prophylaxis and treatment approaches that reflect patient risk profiles and treatment intent.

Operationally, the migration of care from inpatient settings to outpatient clinics and home-based administration has accelerated, propelled by patient preference, cost considerations, and remote monitoring capabilities. Telehealth and digital patient support tools now facilitate symptom tracking and early intervention, reducing unnecessary hospital visits and enabling timely dose administration. From a regulatory and commercial perspective, heightened scrutiny on biologics manufacturing quality, cold chain integrity, and cross-border supply chain resilience has led organizations to invest in redundancy and nearshoring strategies to mitigate disruptions.

Payer and provider behaviors are also transforming as value-based contracting, real-world evidence generation, and outcomes-based reimbursement models gain traction. These mechanisms encourage manufacturers to demonstrate not only clinical efficacy but also measurable reductions in febrile neutropenia incidence, hospitalizations, and total cost of care. Taken together, these shifts are producing a more complex but opportunity-rich environment in which stakeholders who align clinical innovation with patient-centric delivery and robust evidence packages will secure competitive advantage.

Understanding how United States tariff changes in 2025 have reshaped manufacturing, procurement, and clinical access dynamics affecting chemotherapy induced neutropenia therapies

The cumulative impact of United States tariffs implemented in 2025 has introduced a new layer of complexity to the CIN ecosystem, influencing manufacturing strategies, procurement choices, and pricing negotiations. Tariff adjustments on biologics inputs and finished products have prompted manufacturers to reassess global sourcing decisions, accelerate regional manufacturing capacity builds, and seek tariff mitigation strategies through tariff engineering or reclassification where feasible. These strategies have direct operational implications for lead times, inventory policies, and cold chain logistics that are central to maintaining uninterrupted access to G-CSF therapies.

For health systems and payers, the tariff environment has elevated the importance of strategic procurement and formulary management. Hospitals and large clinic networks have responded by reassessing supplier diversification, renegotiating contracting terms, and intensifying scrutiny of total cost of care rather than unit price alone. Meanwhile, manufacturers and distributors have prioritized transparent communication on cost drivers and engaged in collaborative value-sharing conversations with payers to limit patient access disruptions.

Clinicians and pharmacy leaders are navigating the potential downstream effects on therapeutic choice and site-of-care decision-making. In some instances, incremental supply chain costs have encouraged the adoption of alternative administration settings, such as outpatient or home care, to offset facility-related expenses. Throughout this period of adjustment, stakeholders have emphasized robust scenario planning, supply chain visibility, and proactive regulatory engagement to stabilize access and preserve continuity of care for patients at risk of neutropenia.

Deep segmentation insights that connect product characteristics, therapeutic intent, administration routes, and distribution channels to actionable clinical and commercial strategies

Segmentation-driven insights reveal nuanced opportunities and constraints across product portfolios, therapeutic intent, and delivery channels that influence clinical practice and commercial strategy. Based on product type, the competitive environment spans long-acting pegylated agents and emerging molecules such as eflapegrastim alongside established therapies like filgrastim and lipegfilgrastim, which collectively present differentiated profiles in dosing frequency, administration convenience, and cold chain requirements. Based on therapy, the dichotomy between prophylaxis and treatment creates distinct adoption drivers; prophylaxis prioritizes predictable scheduling and adherence, whereas treatment emphasizes rapid neutrophil recovery and acute response.

Based on route of administration, the choice between intravenous injection and subcutaneous injection affects site-of-care selection, nursing workload, and patient preference, with subcutaneous options facilitating outpatient and home-based models. Based on end user, clinics, home care programs, and hospitals demonstrate divergent operational capabilities and reimbursement models, necessitating tailored service offerings and patient support initiatives. Based on distribution channel, hospital pharmacy, online pharmacy, and retail pharmacy pathways each entail different procurement cycles, dispensing protocols, and patient touchpoints that shape adherence and follow-up.

Based on treatment setting, inpatient and outpatient contexts influence timing of prophylaxis, monitoring intensity, and escalation protocols. Based on patient group, adult, geriatric, and pediatric populations require differentiated dosing approaches, safety monitoring, and caregiver education to manage neutropenia risk effectively. Finally, based on dosage strength, standard regimens such as weight-based 5 mcg/kg dosing and fixed 6 mg options create alternate pathways for administration scheduling, patient convenience, and inventory management. Synthesizing these segmentation lenses enables stakeholders to prioritize interventions that align clinical characteristics with operational feasibility and payer expectations.

How regional variations across the Americas, Europe Middle East & Africa, and Asia-Pacific shape access, adoption, and supply chain strategies for neutropenia management

Regional dynamics exert a strong influence on access patterns, regulatory expectations, and operational priorities across the CIN landscape. In the Americas, clinical practice reflects rapid adoption of long-acting G-CSF formulations and a strong emphasis on outpatient and home-based care models, supported by integrated payer-provider systems that incentivize reductions in hospital utilization. Supply chain resilience and domestic manufacturing considerations have become focal points for stakeholders seeking to stabilize access and respond to tariff-driven cost pressures.

In Europe, Middle East & Africa, heterogeneity in regulatory frameworks, reimbursement pathways, and healthcare infrastructure creates a mosaic of adoption rates and procurement behaviors. Some markets favor biosimilar adoption and cost-containment measures, while others emphasize clinical continuity and brand-name therapeutics. The region's diverse treatment settings, from advanced tertiary centers to resource-constrained facilities, necessitate adaptable product portfolios and flexible distribution strategies.

In Asia-Pacific, rapid expansion of oncology services, growing biologics manufacturing capacity, and evolving regulatory harmonization are accelerating availability of both originator and biosimilar G-CSF therapies. Manufacturers that invest in regional manufacturing and local partnership models often realize reduced lead times and enhanced market responsiveness. Across all regions, harmonized pharmacovigilance, cold chain infrastructure, and payer engagement remain essential components for sustained access and scalable adoption of neutropenia management strategies.

Corporate strategies and competitive imperatives centered on innovation, manufacturing resilience, value-based contracting, and integrated patient support models

Competitive behavior among key companies in the CIN space reflects a dual focus on product innovation and commercial execution. Leading biologics developers and their partners are investing in next-generation formulations, real-world evidence programs, and patient support services that reduce barriers to adherence and facilitate outpatient administration. These firms are also expanding manufacturing footprints and implementing quality-by-design approaches to enhance batch reliability and regulatory compliance, thereby strengthening supply chain assurance for temperature-sensitive therapies.

In parallel, several incumbents and new entrants are pursuing differentiated value propositions that combine clinical convenience, cost-effectiveness, and bundled service offerings. Strategic alliances between manufacturers, specialty pharmacies, and home health providers are emerging to streamline patient onboarding, cold chain handling, and follow-up care. Companies that can demonstrate measurable reductions in febrile neutropenia events and hospital admissions through robust data packages and pilot programs are more likely to achieve favorable formulary positions and payer agreements.

Across the competitive set, successful companies emphasize agility in contracting, willingness to participate in outcomes-based arrangements, and investment in digital tools that support adherence and remote monitoring. These capabilities enable organizations to respond to tariff-driven cost pressures, shifting site-of-care preferences, and the increasing demand for patient-centric, value-driven solutions.

Actionable, operationally grounded recommendations for industry leaders to strengthen supply chains, enable home-based care, and secure payer-aligned value propositions

Industry leaders can convert insights into measurable advantage by implementing a set of pragmatic, actionable strategies that align clinical efficacy with operational and commercial objectives. First, invest in supply chain diversification and regional manufacturing to mitigate trade-related risks and to shorten lead times for temperature-sensitive biologics. Complement these investments with enhanced cold chain visibility and contingency inventory policies to preserve continuity of care during disruptions.

Second, prioritize product and service bundles that enable safe home administration and outpatient management, including nurse-led training, digital monitoring platforms, and specialty pharmacy coordination. These approaches reduce facility burden and improve patient experience while supporting adherence to prophylactic regimens. Third, develop robust real-world evidence generation plans and engage payers early to translate clinical impact into reimbursement value, leveraging pilot programs that quantify reductions in febrile neutropenia and associated hospital utilization.

Fourth, adopt flexible contracting and innovative pricing models, such as outcomes-based agreements or risk-sharing arrangements, to address payer concerns and to demonstrate alignment with broader healthcare efficiency goals. Fifth, tailor commercialization strategies to segmentation nuances by aligning product attributes-such as fixed-dose options or weight-based dosing-with the operational capabilities of clinics, hospitals, and home care providers. By executing these recommendations with disciplined change management and cross-functional coordination, industry leaders will position themselves to capture clinical trust and payer support while preserving patient access.

A rigorous, mixed-methods research methodology combining stakeholder interviews, literature synthesis, and supply chain analysis to produce validated and actionable insights

The research approach underpinning this executive summary integrates qualitative and quantitative methods designed to ensure reliability, transparency, and practical relevance. Primary research included structured interviews with clinical leaders in oncology and supportive care, pharmacy directors across hospital and outpatient settings, specialty pharmacy operators, and payer representatives to capture contemporary practice patterns and reimbursement considerations. These stakeholder insights were supplemented by protocol reviews and analyses of published clinical guidelines to contextualize therapeutic decision-making and prophylaxis criteria.

Secondary research leveraged peer-reviewed literature, regulatory guidance documents, and clinical trial registries to validate safety and efficacy considerations for G-CSF therapies and to trace recent regulatory developments. Supply chain and policy analyses incorporated publicly available trade policy documentation and industry advisories to understand the operational implications of tariff changes and manufacturing shifts. Data triangulation methods were applied throughout to reconcile differing perspectives and to identify consistent trends.

Quality assurance measures included cross-validation of interview findings, methodological transparency in data sourcing, and iterative expert review cycles to refine conclusions. Ethical considerations and data privacy were maintained by anonymizing primary interview inputs and by adhering to accepted standards for handling proprietary information. Together, these methods produced a synthesis that balances clinical nuance with operational and commercial intelligence for decision-makers.

A conclusive synthesis emphasizing the necessity of coordinated clinical, commercial, and operational strategies to secure patient access and long-term value in neutropenia management

In conclusion, the management of chemotherapy induced neutropenia is at an inflection point where clinical innovation, shifting care delivery models, supply chain dynamics, and evolving reimbursement expectations converge. Stakeholders that proactively integrate long-acting therapeutic options, enable safe outpatient and home-based administration, and invest in resilient manufacturing and distribution will be best positioned to safeguard patient access and demonstrate value to payers. Tariff-driven pressures and regional variability require strategic adaptation, yet they also present opportunities for competitive differentiation through localized manufacturing and service innovation.

Decision-makers should approach CIN strategy holistically, aligning clinical protocols, commercial models, and operational capabilities to deliver measurable improvements in patient outcomes and health system efficiency. By adopting targeted segmentation strategies, engaging payers with robust evidence packages, and prioritizing patient-centric delivery, organizations can navigate current headwinds and capture long-term opportunities created by the transition to value-focused oncology care. This synthesis underscores the imperative for coordinated action across clinical, commercial, and operational domains to achieve sustainable improvement in neutropenia management.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of long-acting pegfilgrastim biosimilars improving prophylaxis access and affordability for diverse oncology populations
  • 5.2. Integration of AI-driven risk stratification tools for personalized neutropenia prevention and treatment planning in clinical settings
  • 5.3. Adoption of oral myeloid growth factors to enhance patient convenience and adherence in community oncology practices
  • 5.4. Rising emphasis on real-world evidence generation to demonstrate cost-effectiveness and outcomes of neutropenia interventions
  • 5.5. Growth of telehealth-supported neutropenia management programs for remote monitoring and early intervention in rural patient cohorts
  • 5.6. Emergence of value-based reimbursement models linking neutropenia treatment outcomes to payer contracting and pricing strategies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chemotherapy Induced Neutropenia Market, by Product Type

  • 8.1. Eflapegrastim
  • 8.2. Filgrastim
  • 8.3. Lipegfilgrastim
  • 8.4. Pegfilgrastim

9. Chemotherapy Induced Neutropenia Market, by Therapy

  • 9.1. Prophylaxis
  • 9.2. Treatment

10. Chemotherapy Induced Neutropenia Market, by Route Of Administration

  • 10.1. Intravenous Injection
  • 10.2. Subcutaneous Injection

11. Chemotherapy Induced Neutropenia Market, by End User

  • 11.1. Clinic
  • 11.2. Home Care
  • 11.3. Hospital

12. Chemotherapy Induced Neutropenia Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Chemotherapy Induced Neutropenia Market, by Treatment Setting

  • 13.1. Inpatient
  • 13.2. Outpatient

14. Chemotherapy Induced Neutropenia Market, by Patient Group

  • 14.1. Adult
  • 14.2. Geriatric
  • 14.3. Pediatric

15. Chemotherapy Induced Neutropenia Market, by Dosage Strength

  • 15.1. 5 Mcg/Kg
  • 15.2. 6 Mg

16. Chemotherapy Induced Neutropenia Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Chemotherapy Induced Neutropenia Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Chemotherapy Induced Neutropenia Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. Competitive Landscape

  • 19.1. Market Share Analysis, 2024
  • 19.2. FPNV Positioning Matrix, 2024
  • 19.3. Competitive Analysis
    • 19.3.1. Amgen Inc.
    • 19.3.2. Teva Pharmaceutical Industries Ltd.
    • 19.3.3. Sandoz International GmbH
    • 19.3.4. Pfizer Inc.
    • 19.3.5. Viatris Inc.
    • 19.3.6. Biocon Ltd.
    • 19.3.7. Fresenius Kabi AG
    • 19.3.8. Intas Pharmaceuticals Ltd.
    • 19.3.9. Cipla Ltd.
    • 19.3.10. Lupin Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2032 (%)
  • FIGURE 17. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. ASEAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GCC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. EUROPEAN UNION CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BRICS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. G7 CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. NATO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 34. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 35. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 36. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY EFLAPEGRASTIM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY EFLAPEGRASTIM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY EFLAPEGRASTIM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY EFLAPEGRASTIM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY EFLAPEGRASTIM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY EFLAPEGRASTIM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY FILGRASTIM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY FILGRASTIM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY FILGRASTIM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY FILGRASTIM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY FILGRASTIM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY FILGRASTIM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY LIPEGFILGRASTIM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY LIPEGFILGRASTIM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY LIPEGFILGRASTIM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY LIPEGFILGRASTIM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY LIPEGFILGRASTIM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY LIPEGFILGRASTIM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEGFILGRASTIM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEGFILGRASTIM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEGFILGRASTIM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEGFILGRASTIM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY OUTPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 5 MCG/KG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 5 MCG/KG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 5 MCG/KG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 5 MCG/KG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 5 MCG/KG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 5 MCG/KG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 6 MG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 6 MG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 6 MG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 6 MG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 6 MG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 6 MG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLIO